Research work · 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Yuriy Janjigian, Kohei Shitara, Markus Hermann Moehler
The Lancet